Browsing Tag
CARsgen Therapeutics Holdings Limited
3 posts
CARsgen showcases early clinical results for CT0596 allogeneic BCMA CAR-T cell therapy in multiple myeloma
CARsgen unveils early CT0596 CAR-T trial results at ASH 2025, showing deep responses and strong tolerability in multiple myeloma. See what’s next for the therapy.
CARsgen’s CT0596 CAR-T shows strong early results in refractory myeloma
CARsgen’s allogeneic CAR-T therapy CT0596 shows early safety and efficacy in myeloma—find out how investors are reacting to the 2025 breakthrough.
CARsgen advances CAR T-cell therapies with breakthrough designation for satri-cel and first dose of KJ-C2219
CARsgen Therapeutics Holdings Limited has taken significant strides in the field of CAR T-cell therapy with two major…